Back

Effect of sacubitril/valsartan and SGLT2 inhibitors on echocardiographic response and clinical outcomes after cardiac resynchronization therapy: insights from a real-world cohort

10 May 2026 (11:30 - 12:15)
Organised by: Logo
Congress Presentation Part of: Advanced pharmacotherapy in complex heart failure scenarios Cardiac Resynchronisation Therapy (CRT) HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Isabel Martins Moreira

Hospital Center of Tras-os-Montes and Alto Douro, Vila Real (Portugal)

6 More presentations in this session

Presentation thumbnail
Efficacy and safety of sacubitril-valsartan versus enalapril in patients with heart failure due to Chagas cardiomyopathy: a systematic review and meta-analysis
Doctor B. Aziri (Sarajevo, BA)
Abstract Slides Video
Presentation thumbnail
Improved subgroup treatment effect estimation in heart failure trials using Bayesian hierarchical shrinkage models
Doctor A. Henderson (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Sacubitril/valsartan, initial dip in estimated glomerular filtration rate, and clinical outcomes in patients with heart failure
Doctor M. Manabe (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Guideline directed medical therapy in patients with heart failure with reduced ejection fraction undergoing renal replacement therapy: real world experience from a specialized cardiorenal unit
Doctor S. Ruiz Bustillo (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of sacubitril/valsartan in the management of heart failure with reduced ejection fraction and chronic kidney disease: a systematic review and meta-analysis
Doctor B. Chan Chin (Limerick, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Advanced pharmacotherapy in complex heart failure scenarios

The Event

Event poster

Heart Failure 2026

10 May 2026 11:30 CET
You may be interested in
thumbnail
Congress Presentation
Appropriate device therapies after CRT-D implantation in the modern heart failure treatment era
thumbnail
Congress Presentation
A time-dependent analysis of sacubitril/valsartan and gliflozins benefits in patients receiving cardiac resynchronization therapy
thumbnail
Congress Presentation
Impact of heart failure chronicity on long-term outcomes after cardiac resynchronization therapy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources